Howard A Liebman
Overview
Explore the profile of Howard A Liebman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
2937
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Modi D, Chowdhury S, Chowdhury S, Mahamad S, Modi H, Cines D, et al.
Thromb Haemost
. 2024 Dec;
PMID: 39719150
The McMaster Immune Thrombocytopenia (ITP) Summit, held on October 27, 2023, was an educational seminar from leading experts in immune thrombocytopenia and related disorders geared toward hematologists, internists, immunologists, and...
2.
Kuter D, Bussel J, Ghanima W, Cooper N, Gernsheimer T, Lambert M, et al.
Ther Adv Hematol
. 2023 Oct;
14:20406207231205431.
PMID: 37869360
Background: Immune thrombocytopenia (ITP) is characterized by primarily autoantibody-mediated platelet destruction and impaired platelet production resulting in thrombocytopenia and an increased risk of bleeding. Other manifestations include increased risk of...
3.
Lee E, Beltrami-Moreira M, Al-Samkari H, Cuker A, DiRaimo J, Gernsheimer T, et al.
Blood
. 2021 Sep;
139(10):1564-1574.
PMID: 34587251
Cases of de novo immune thrombocytopenia (ITP), including a fatality, following SARS-CoV-2 vaccination in previously healthy recipients led to studying its impact in preexisting ITP. In this study, 4 data...
4.
Cuker A, Liebman H
Res Pract Thromb Haemost
. 2021 Sep;
5(6):e12592.
PMID: 34466771
Corticosteroids remain a crucial component of first-line therapy for immune thrombocytopenia (ITP) due to low cost, high initial response rates, and acceptable short-term tolerability. However, extended and recurrent use of...
5.
Schifferli A, Cavalli F, Godeau B, Liebman H, Recher M, Imbach P, et al.
Front Med (Lausanne)
. 2021 Jul;
8:613192.
PMID: 34249957
The pathogenesis of immune thrombocytopenia (ITP) is increasingly being elucidated, and its etiology is becoming more frequently identified, leading to a diagnostic shift from primary to secondary ITP. The overlap...
6.
Cuker A, Despotovic J, Grace R, Kruse C, Lambert M, Liebman H, et al.
Res Pract Thromb Haemost
. 2021 Feb;
5(1):69-80.
PMID: 33537531
Background: Thrombopoietin receptor agonists (TPO-RAs) are used to treat primary immune thrombocytopenia (ITP). Some patients have discontinued treatment while maintaining a hemostatic platelet count. Objectives: To develop expert consensus on...
7.
8.
Newland A, Sanchez-Gonzalez B, Rejto L, Egyed M, Romanyuk N, Godar M, et al.
Am J Hematol
. 2019 Dec;
95(2):178-187.
PMID: 31821591
Primary immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder, characterized by a low platelet count (<100 × 10 /L) in the absence of other causes associated with thrombocytopenia. In...
9.
Piatek C, Bocian H, Algaze S, Weitz I, OConnell C, Liebman H
Acta Haematol
. 2019 Oct;
143(3):244-249.
PMID: 31665725
The combination of rituximab, cyclophosphamide, and dexamethasone (RCD) is highly effective in the treatment of warm autoimmune hemolytic anemia (WAIHA) associated with chronic lymphocytic leukemia (CLL). We treated a cohort...
10.
Key N, Khorana A, Kuderer N, Bohlke K, Lee A, Arcelus J, et al.
J Clin Oncol
. 2019 Aug;
38(5):496-520.
PMID: 31381464
Purpose: To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer. Methods: PubMed and the Cochrane Library were searched for randomized controlled trials (RCTs)...